Lakefront Biotherapeutics (GLPGF) Capital Expenditures Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Capital Expenditures Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 23.70% |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | 0.24% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 23.48% |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 63.07% |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | -45.93% |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 29.63% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -16.79% |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 68.43% |
| Dec 31, 2025 | 59.42% |
| Mar 31, 2025 | 19.57% |
| Dec 31, 2024 | 54.63% |
| Jun 30, 2024 | 35.23% |
| Mar 31, 2024 | 26.50% |
| Dec 31, 2023 | 26.50% |
| Mar 31, 2023 | -13.10% |
| Dec 31, 2022 | -4.09% |
| Mar 31, 2022 | -62.73% |
| Dec 31, 2021 | -73.56% |
| Jun 30, 2021 | -82.59% |
| Mar 31, 2021 | -91.22% |
| Dec 31, 2020 | -100.88% |
| Jun 30, 2020 | 85.89% |
| Mar 31, 2020 | -48.00% |
| Dec 31, 2019 | -72.66% |
| Jun 30, 2019 | -17.31% |
| Mar 31, 2019 | -28.39% |
| Dec 31, 2018 | -21.06% |